EIF2AK3 and medulloblastoma: Importantly, using the VEGFR2 inhibitor SU5416 and the NAB to block VEGF-A/VEGFR2 signaling, our results suggested that VEGF-A was required for the promoting effects of PERK activation on medulloblastoma cell migration and invasion.